INNOCARE (09969.HK) Financial Statements - Balance Sheet/Income Statement/Cash Flow - Longbridge

Quote List Quote List

Event Tracking

Nov28

Nocigna Completes First Patient Dosing for Global Phase II Clinical Trial of TYK2 Inhibitor Soficitinib

00:34

Nov18

CITIC Securities Maintains Buy Rating on Noego and Sets Target Price

05:12

Company Responds to Investor Inquiries on Drug R&D and Sales Progress

01:33

Nov17

UBS Adjusts Nomura Cansa Health Target Price to 23.6 HKD

08:42

Nov14

InnoCare Pharma Reports Strong Q3 2025 Revenue Growth, Orelabrutinib Sales Surge

11:02

Nov13

INNOCARE released FY2025 Q3 earnings on November 13 After-Market (BJT), actual revenue HKD 419.66 M (forecast HKD 418.26 M), actual EPS HKD -0.0205

11:00

Schedules & Filings

Schedules

Filings

Nov13

Earning Release(CST)

FY2025 Q3 Earning Release (HKD) Revenue 419.66 M, Net Income -37.52 M, EPS -0.0205

Aug19

Earning Release(CST)

FY2025 Q2 Earning Release (HKD) Revenue 383.27 M, Net Income -52.6 M, EPS -0.0433

May13

Earning Release(CST)

FY2025 Q1 Earning Release (HKD) Revenue 408.32 M, Net Income 19.24 M, EPS 0.0107

View More

Stock List

Top Gainers

Top Decliners

Main Board

Symbol

Price

%Chg

Change

View More